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Abstract
In the past 22 years, 32 states have legalized and regulated marijuana for medical use.
However, marijuana is scheduled as a Schedule I drug according to the federal government. This
means that states have no specific regulations to follow for regulating marijuana for medical use.
Because of this, states may be risking the safety of medical marijuana patients. Research was
conducted to analyze the policies set out by the Food & Drug Administration (FDA) regarding
the regulation of a prescription drug. Since the FDA is responsible for the safety and efficacy of
prescription drugs, this analysis included what types of risks were mitigated by FDA policies.
State policies on medical marijuana were then compared to FDA policies in order to determine if
aforementioned risks are being acknowledged and mitigated by states. This research found that
states are implementing some policies similar to aspects of FDA regulations, but states are not
eliminating nearly as many safety risks that the FDA focuses on eliminating. States are, however,
creating additional policies that encompass social issues regarding the legalization of medical
marijuana, which the FDA doesn’t do, which could be allowing medical safety to be analyzed in
a broader social context.
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Chapter I. Introduction
The use and acceptance of medical marijuana in the United States is evidenced by an
increasing number of states that have passed legislation to legalize its use. While there is a long
history of pharmaceutical regulation in the United States, medical marijuana is illegal at the
federal level of government. Thus, regulation rests at the state level, where there are significantly
different regulatory standards across these states. The level and type of regulation for marijuana
as a medication across all states is significantly less than the level of regulation for traditional
pharmaceuticals.
Marijuana is considered a Schedule I drug and thus illegal at the Federal level of
government. According to the Drug Enforcement Administration, a Schedule I drug is a drug
“with no currently accepted medical use and high potential for abuse” (U.S. Drug, 2018). This
classification aligns marijuana with drugs like heroin, ecstasy, and lysergic acid diethylamide
(LSD). However, in 1996, California passed Proposition 215 which legalized the medical use of
cannabis. By 1998, three additional states (District of Columbia, Oregon, and Washington state)
had also legalized marijuana for medical use. President Clinton, however, reiterated his
opposition to medical marijuana use and threatened to take away the prescribing rights of doctors
who suggested medical marijuana use to their patients. A group of physicians in San Francisco,
however, challenged this and prevailed in Conant v. McCaffrey. This case prohibited the
punishing of physicians or taking their DEA licenses for recommending medical use of
marijuana (Conant, 2000). In 2005, during the Bush administration, Gonzales v. Raich ruled in
favor of the federal government’s ability to enforce federal laws in states that had already
legalized medical marijuana, specifically in terms of production and use of homegrown
marijuana (Gonzales, 2005). In 2014, during the Obama administration, the Rohrabacher-Farr
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amendment was finally passed, after being defeated 6 times since 2001. This amendment
describes how the Justice Department is prohibited from spending funds to interfere with the
implementation of state medical marijuana laws. The passing of this amendment was the first
time in Congress’ history that voting swayed to protect medical marijuana patients, and was
viewed as a historic victory for those patients.
In the five years since 2014, 11 states have implemented medical marijuana policy. This
is a large yearly increase when compared to the 21 states that implemented policies in the 18
years prior to the passing of the Rohrabacher-Farr amendment. Although more states are passing
policies regarding medical marijuana, states are not doing so consistently. The Food & Drug
Administration (FDA) has a specific protocol for regulating medical drugs. However, due to the
duality of legalization in the United States, the FDA is not allowed to regulate the use of medical
marijuana and it continues to prove difficult for states to regulate in a standardized manner.
While this may prove to be good for policy innovation, it is unclear if the risks associated with
the lack of standards should or can be remedied. While there is variation between state policies
for medical marijuana regulation, the regulation for pharmaceutical drugs are clear and outlined
by the FDA. The FDA uses the Code of Federal Regulations to publish the regulations for
regulating drugs for medicinal use.
In this thesis, I will be looking at the difference between the standards of traditional
pharmaceutical regulation and the current state of regulation of medical marijuana across a
number of states. This is important to study because states currently have no standardization for
regulating medical marijuana, which could be jeopardizing the safety of medical marijuana
patients. I will identify the goals of different regulatory steps in the traditional processes, and
compare these steps to current state regulations of medical marijuana. Through this comparison,
5

I will identify where current medical marijuana law may be lax, and perhaps inadequately
protecting the safety of patients. I will then compare this to what is currently known about the
impacts of state legalization to see if any of these potential problems have come to fruition.
The next section will be a review of previous research conducted on the implications of
medical marijuana legalization. From this literature, I will identify my specific research
questions, outline a methodology for data collection, and describe the data and findings of
research. This will be followed by analysis and discussion, as well as research limitations and
policy recommendations.
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Chapter II. Literature Review
Since medical marijuana is approved as a medicinal drug in many states, it is important to
look at the known risks of this type of drug. The purpose of this literature review is to see what
studies have been conducted on the risks associated with medical marijuana legalization. It
analyzes the most common impacts on society that has been studied thus far, including increased
use of recreational marijuana, youth use, public health effects, traffic fatalities, crime and suicide
rates, and more.
Methodology
I focused my search results on the implications of implementing medical marijuana laws.
Utilizing Google Scholar, research was conducted to find only the implications of medical
marijuana once a law or policy was implemented. Some research spanned the United States,
while other research only touched a specific group of states, or one single state. Additionally,
research spans the whole history of medical marijuana, which is a fairly short timeline (20042017). During a preliminary search, I found multiple categories of outcomes studied, including
increased use of recreational marijuana, youth use, crime, public health effects, traffic fatalities,
suicide, and a change in attitude. Once I discovered the main topics, I delved into them
individually. This search included phrases like “legalization of medical marijuana on crime” and
“legalization of medical marijuana on suicide rates.” All of the statistics of these implications
were studied after the implementation of medical marijuana laws and compared to what the
statistics were prior to the implementation of the laws. In this review, I have excluded any
research that was not exclusively about medical marijuana. This included any papers analyzing
effects of marijuana in general, as well as papers discussing implications of legalizing marijuana
for recreational use. While some academic scholarship focused on the ethical dilemma and
7

duality of medical marijuana legislation in the United States, I will not consider the research on
ethics, and instead will focus on the seven main categories of study regarding the implementation
of medical marijuana laws.
Findings
Summary
The seven main categories of research on the impacts of medical marijuana legalization
are: increased use of marijuana, increased youth use (particularly adolescents), effects to the
public health system, traffic accidents & fatalities, crime rates, suicide rates and a change in
attitude regarding marijuana. A total of 25 articles were found covering these topics. Across the
25 articles, a few revolved around each topic—with the most research being conducted on
increased youth use and traffic accidents and fatalities. Table 1 shows the topics covered in each
of the articles reviewed. Additionally, Table 2 shows the general findings of each category,
while the remaining sections discuss more specific findings for each of these topics.
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Table 1: Topics Covered in the 25 Articles Reviewed

Traffic Suicide
Citations Rates

Public
Health
Effects

Increased Youth
Use
Use
Crime

Changing
Attitude

Pediatric
Potency Exposure

Citation
Anderson
(2013)

x

Anderson
(2014)

x

Bradford
(2016)

x
x

Cerda (2011)

x

Choo (2014)

x

Chu (2014)

x

Davis (2016)

x
x

Friese (2012)

x

Grucza (2015)

x

Hasin (2015)
Khatapoush
(2004)

x

LynneLandsman
(2013)
Masten (2014)

x
x
x

Miech (2015)

x

Morris (2014)
Rylander
(2014)
SalomonsenSautel (2014)

x
x

SalomonsenSautel (2012)
SantaellaTenorio (2017)
Sevigny (2014)
Wang (2013)

x

x
x
x
x
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Table 2: Summary of Article Findings, Based on Categories
Overall
Findings

Comments

Category

# of
Articles

Youth Use

5

Mixed

No correlation for national sample. Increased
use when looking at specific region.

Traffic
Incidents

4

Mixed

Lower fatality rates, but higher number of
marijuana-positive drivers in accidents.

Increased Use

3

Mixed

Increased use for national sample. No
correlation when looking at specific regions.

Suicide Rates

3

Mixed

No correlation in one national study and in
regional study. One national study found
reduction.

Change in
Attitude

2

Positive

Decreased perceived harm.

Public Health
Effects

2

Mixed

Lower prescription drug use and increase in
hospital admissions.

Crime Rate

2

Mixed

Increase in marijuana arrests, but no correlation
to other crimes.

Increased Use
Two articles utilized the National Epidemiologic Survey on Alcohol and Related
Conditions to determine if use of marijuana increased after medical marijuana laws were
implemented (Cerda, 2011; Hasin, 2015). It was concluded that recreational marijuana use more
than doubled after the implementation of policies regarding medical marijuana. In addition, the
likelihood of marijuana abuse/dependency increased in states with medical marijuana laws.
However, a study conducted in California (Khatapoush, 2004) found no increase of drug use
after the implementation of medical marijuana laws. This is likely because of the decreased
10

sample size. This research demonstrates that policy makers should be aware of potential overuse
and abuse of marijuana after the implementation of medical marijuana laws.

Youth Use
Two articles analyzed increased youth use of marijuana across multiple states (Choo,
2014; Lynne-Landsman, 2013). Using surveys, there was no statistically significant difference in
marijuana use before and after policy change or implementation. Two other articles conducted
surveys in one specific state (Friese, 2012; Miech, 2015). When research was conducted with a
narrower sample size of just one state, more statistically significant results were found. In
Montana (Friese, 2012), 31% of 8th, 10th, and 12th grade students reported having had used
marijuana in their lifetime. Similarly, in California and after the decriminalization of marijuana
(Miech, 2015), 25% of 8th, 10th, and 12th graders said they were more likely to have used
marijuana in the past 30 days. One study conducted research in the Denver metropolitan area
and found that 74% of adolescents had used someone else’s medical marijuana (SalomonsenSautel, 2012). This research shows how drastically results change based on area and local versus
national level data. When looking at national data, the results appear to wash out.

Public Health Effects
The legalization of medical marijuana has impacted the public health system. For
example, one study was conducted on how the implementation of medical marijuana policies
impacted the use of all FDA-approved prescription drugs paid for by the Medicare Part D
program (Bradford, 2016). Using data from the Medicare Part D Prescription Drug Event
Standard Analytic file and restricting the analysis to any prescription drugs that treated
conditions for which medical marijuana could be a treatment, the author found that medical
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marijuana laws caused prescriptions drug use that served as alternatives to fall drastically – with
Medicare spending an estimated $165.2 million less than in previous years. In addition, a study
in Colorado (Davis, 2016) found that there was an increase in hospital discharges, poison center
calls, and decreases in treatment entries after the legalization of medical marijuana.

Traffic Incidents
Two articles used the Fatality Analysis Reporting System collected by the National
Highway Traffic Safety Administration to determine if there was a correlation between traffic
incidents and the legalization of medical marijuana (Santaella-Tenorio, 2017; Anderson, 2013).
Both found that, on average, states with medical marijuana laws had lower traffic fatality rates
than states without medical marijuana laws. On the other hand, a study conducted in Colorado
(Salomonsen-Sautel, 2014) found that a larger proportion of drivers in fatal motor vehicle
crashes were marijuana-positive after commercial availability of medical marijuana increased.
Similarly, one study of 12 states (Masten, 2014) found that only a few states—California,
Hawaii, and Washington State—had an increased driver cannabinoid prevalence associated with
the implementation of medical marijuana laws.

Crime Rates
The implementation of medical marijuana laws has led to changes in crime rate. Two
studies were conducted across the United States. One study (Chu, 2014) found that the passing of
medical marijuana legislation led to a 10-20% increase in marijuana arrests, while the other
study (Morris, 2014) found that medical marijuana laws were not predictive of higher crime
rates. In particular, the study found no correlation for increased crime rates of homicide, rape,
robbery, assault, burglary, larceny, and auto theft.
12

Suicide Rates
Three studies were conducted regarding suicide rates after the implementation of medical
marijuana laws. Two of them were conducted across the entirety United States, utilizing the
National Vital Statistics System (Anderson, 2014; Grucza, 2015). While Anderson (2014) found
that legalization of medical marijuana was associated with a reduction in suicide rates of men
aged 20-39, Grucza (2015) found that there was no association between medical marijuana
policy and suicide risk in ages 15 and older. A third study (Rylander, 2014) was conducted in
Colorado and also found that there was no significant correlation between the number of medical
marijuana registrants and suicides.

Change in Attitude
Two studies elaborated on the change in attitude regarding marijuana once a medical
marijuana legislation was put into place. Both Khatapoush (2004) and Miech (2015) looked at
California and noticed that perceived harm of medical marijuana decreased, particularly after the
media cover of decriminalization of marijuana.

Other
Furthermore, other categories were mentioned, but not well studied. First, one article
analyzed how the potency of marijuana changed after the implementation of medical marijuana
laws (Sevigny, 2014). Studying nearly 40,000 marijuana samples that were seized by law
enforcement, it was found that potency increased by 0.5% after legalization of medical
marijuana. This increased to 1% more potent in states that had retail dispensaries. Secondly, a
study analyzed data from hospital emergency departments within Colorado (Wang, 2013). The
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study found that there were higher unintentional marijuana ingestions by young children after
decriminalization of marijuana.

Discussion
To summarize, this literature review focused on the effects of implementing medical
marijuana policies. Some findings were consistent, while others were not. There also was not a
large number of articles in any one category. This demonstrates just how new this topic is.
Considering the first state to legalize marijuana for medical purposes was California in 1996,
limiting the ability of researchers to study the impact of these laws. Overall, the research I found
revolved around the societal impacts of implementing medical marijuana policies, such as youth
use, traffic incidents, increased recreational use, suicide and crime rates, public health effects,
change in attitude, potency, and pediatric exposure. While all of the categories appeared to be
under-researched, potency and pediatric exposure proved to be even more so - by only having
one study available on each. While this research does address some of the risks associated with
medical marijuana legalization, there are many risks that are not considered. This includes safety,
efficacy, and potency of medical marijuana. These are things that should be considered when
regulating a substance as a medicinal drug. All in all, however, the majority of research appears
to be regarding the implications of medical marijuana policies and not much regarding the safety
or efficacy.
Three articles analyzed the potential relationship between medical marijuana laws and
their implications by examining the importance of policy dimensions, such as registration
requirements, home cultivation, and dispensaries, as well as when the particular policy
dimensions were enacted (Pacula, 2014; Cohen, 2010; Clark, 2011). There is no standard for
14

each state to follow, so there is plenty of room for discrepancies and small differences between
states’ medical marijuana policies.
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Chapter III. Research Questions
Given this literature review, it can be seen that there are gaps in the research on the
impacts of legalizing medical marijuana. While there was a lack of research on the medical
efficacy of medical marijuana, there was also evidence that legalizing marijuana for medical use
has a secondary impact on society, including increased use, youth use, public health effects,
traffic fatalities, crime and suicide rates, and more. The focus of this research on secondary
impacts suggests that regulation of medical marijuana may serve to protect society not from the
traditional FDA focus on safety and efficacy, but instead on the above societal impacts. Thus,
research for this thesis will focus on answering the following:
1) How does the regulation process of individual states compare to the FDA regulation
processes for pharmaceuticals?
2) What might these differences predict about potential issues of safety and efficacy, and
how does this compare to current research findings on the issue?
3) Do states take appropriate actions and apply certain steps to mitigate risks that are of
most concern?
4) Could the effects displayed in the literature review be mitigated by following FDA
regulations, instead of individual states policies?
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Chapter IV. Methodology
Study Design & Data Collection
My research design is a comparative study that looks at the way states regulate medical
marijuana, as compared to the regulation processes set out by the FDA. This comparison will be
made by mapping out the regulations of the FDA and the regulations of the states of study, to
find similarities and differences between state & federal regulations.
To begin, I will be looking at the National Conference of State Legislators. This will
provide me with a starting point regarding which states have policies and regulations for medical
marijuana. Appendix 1 is a matrix that shows which states in the United States have which type
of cannabis policy dimensions. This shows policy dimensions such as whether states have or
require patient registry or ID cards, if states allow dispensaries, specific medical conditions that
medical marijuana can be used for, and whether states will recognize patients from other states.
Analysis of state policies will be visually easier to identify from this matrix, allowing for easy
comparison across states.
In total, 23 states were selected for study. This included: Arizona, California, Colorado,
Connecticut, DC, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan,
Minnesota, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, Oregon,
Rhode Island, Vermont, and Washington. The matrix in Appendix 1 also includes the specific
piece of legislation from each state of study that legalized marijuana for medical use. Using this
matrix, I looked into each state’s specific legislation, adding additional columns to the table that
contain how that state legalized medical marijuana and how they regulated medical marijuana. In
terms of state legislation of medical marijuana, this refers to a Senate or House bill, an indirect
initiated state statute, an initiated state statute, or an initiated constitutional amendment. Some
17

states have specified the process of regulation in a separate document than that which legalized
medical marijuana. For example, Arizona legalized medical marijuana through an initiated state
statute, but then had a separate Senate Bill passed to discuss the regulation process of medical
marijuana (Americans, 2018). This will also be documented for each state.
Each state specifies which department will be responsible for regulating medical
marijuana. This varies dramatically by state and can include the Department of Health, new
departments like the Medical Marijuana Authority Division, the Medical Marijuana Commission,
or the Office of Medical Cannabis. Some states also utilize the Department of Licensing &
Regulatory Affairs. The department responsible for regulating medical marijuana and the
specifics of each policy will be documented for each state. While the regulations vary among
states, all state regulations do have common threads - including regulations regarding labelling,
dispensaries, testing, and which medical conditions medical marijuana applies to. Many of these
state regulations are similar to the Food & Drug Administration’s regulations for medical drugs.
I will look at 23 states who have legalized and regulated marijuana for medical use. I
have eliminated Utah and Alaska in the list of states I am analyzing; while they both have
legalized marijuana for medical use, they have non-regulated medical marijuana programs. I also
eliminated states that still have pending policies or states that were regulated after 2016, since
some data is only available for medical marijuana policies implemented before 2016.
Next, as seen in Appendix 2, I created a second matrix of all states policies versus FDA
policies for pharmaceutical drugs. This allows for a comparison of policy dimensions of each
state versus corresponding sections of FDA regulations of traditional pharmaceutical drugs.
From this matrix, additional tables were created to show which states have, or don’t have, more
specific regulations within each of those sections. Analysis was conducted to determine if the
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gaps in state policies, or FDA policies, are unimportant or critical. This was done by assigning
goals or risks to each section.
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Chapter V. Results
FDA Regulations
The FDA uses the Code of Federal Regulations to publish their regulations for regulating
drugs for medicinal use. The Code of Federal Regulations (CFR) is a codification of general and
permanent rules and regulations published by executive departments and agencies of the federal
government of the United States (National, 2018). It is published annually and about 10 titles are
published on a quarterly basis. FDA regulations are in Title 21; this title governs food and drugs
within the United States for three main agencies. Each agency has a chapter within the title.
Chapter 1 belongs to the FDA, Chapter 2 belongs to the Drug Enforcement Agency, and Chapter
3 belongs to the Office of National Drug Control Policy. Chapter 1 is then comprised of 1,299
sections, with sections 200 - 370 being dedicated to regulations of pharmaceutical drugs. These
sections are reflected below, along with their significance when it comes to regulating
pharmaceutical drugs.

Labeling
Part 201 of the CFR is dedicated to regulations regarding labeling. It emphasizes the need
for drugs to be labeled with all names of the manufacturers, along with anyone else who has
handled the drug in any way, as well as the need for the facility location in which it was
manufactured (§201.1). The labeling regulations also include the need for National Drug Code
numbers (§201.2). Additionally, the labels must include adequate directions for use and a
statement of ingredients in the drug (§201.5, §201.10). The FDA also requires the label to have
an expiration date and a lot number (§201.17, §201.18). In general, labeling requirements must
include a summary for the safe and effective use of the drug, must be informative and accurate,
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not promotional, false or misleading, and have no implied claims or suggestions for use if
evidence of safety or efficacy is lacking. While it is true that proper labels give patients the
information on how to properly take medications, the primary purpose of labeling is to give
healthcare professionals the information they need to prescribe drugs appropriately.

Prescription Drug Advertising and Prescription Drug Marketing
Parts 202 and 203 are dedicated to regulations regarding advertising and marketing,
respectively. Some states use advertising and marketing interchangeably, while the FDA has a
clear definition of the two. Marketing is the process involving design, creation, research and data
mining about how to best align the idea of a product with the target audience. Advertising, on the
other hand, is the literal process of making the product known to an audience and is typically the
description used to present the product to the general public (Concordia 2019).
The FDA has a set of regulations specifically for advertisements of pharmaceutical drugs.
The basics of these regulations include different types of advertisements, including product claim
advertisements, reminder advertisements, and help-seeking advertisements. The regulations also
include the scope of information that should be included in an advertisement. This can include
effectiveness and side effects of the drug. While the specific regulations vary slightly based on
the type of advertisement, the majority of the regulations are designed to ensure that there is no
false or misleading information on any advertisement. Similar to the labelling regulations, this
ensures that information is being portrayed to patients and healthcare professionals truthfully,
allowing them to take and prescribe drugs correctly.
Additionally, the FDA has a set of regulations for marketing of pharmaceutical drugs.
The purpose of the marketing regulations are to implement the Prescription Drug Marketing Act
of 1987 in order to protect the public, and to protect the public against drug diversion by
21

establishing procedures, requirements, and minimum standards for the distribution of
prescription drugs (§203.2). The marketing regulations focus on reimportation, sales restrictions,
samples, and wholesale distribution of pharmaceutical drugs. These regulations are put in place
in order to protect the general public and their health. Marketing, and advertising, regulations
help assure the safety, effectiveness, and security of prescription drugs by allowing people to get
the accurate information they need to use prescriptions appropriately and improve their health.

Medication Guides for Prescription Drug Products
Part 208 outlines the regulations for medication guides. Medication guide means FDAapproved patient labeling conforming to the regulations outlined in Part 208 (§208.3). The
regulations include the content and format of the medication guide, including how the guide
should be written in understandable English, with non-technical and non-promotional wording
(§208.20). The medication guide must also include the following headings, followed by a
detailed paragraph answering the questions stated in the headings:
● “What is the most important information I should know about {name of drug}?
● What is {name of drug}?
● Who should not take {name of drug}?
● How should I take {name of drug}?
● What should I avoid while taking {name of drug}?
● What are the possible risks or reasonably likely side effects of {name of drug}?”
(§208.20)
The regulations also indicate when and how to distribute and dispense a medication guide, as
well as exemptions to these regulations (§208.24, §208.26). The purpose of the medication guide
is to inform patients and consumers of the prescription drugs of all information regarding the
22

proper use of the drug. It can be seen, with much more specific regulations here than are found in
labelling, that medication guides are more specifically for patients. Therefore, the nomenclature,
content, and format are all geared more toward consumers, which can be seen with the very
specific headings.

Requirements for Authorized Dispensers and Pharmacies to Distribute a Side Effects Statement
Part 209 outlines the requirements for distributing side effects statements and warnings.
This section specifies content and format of the side effects statement. The content must read
“Call your doctor for medical advice about side effects. You may report side effects to FDA at 1800-FDA-1088,” and the format of said content must be a clear, single, easy-to-read line with a
specified letter type (§209.10). Additionally, the section describes when and how to distribute
and dispense the side effects statement (§209.11). The issuing of a side effects statement is
important because all medications can cause unwanted side effects. Some side effects are not as
severe as others - for example, some medications can cause a simple rash, while others can cause
death. Regardless of the severity of a side effect, it is important that all known side effects are
disclosed so that patients can be aware of adverse reactions that may potentially occur in their
body while taking certain drugs, or if the patient even wants to take the drug in the first place.

Current GMP in Manufacturing, Processing, Packing of Holding of Drugs; General and Current
GMP for Finished Pharmaceuticals
Parts 210 and 211 are dedicated to regulations regarding good manufacturing practices
(GMPs) during manufacturing, processing, packing and holding of drugs (§210) and for finished
pharmaceuticals (§211). Part 210 mainly outlines the current status of GMPs, the applicability of
GMP regulations within the pharmaceutical industry, and concludes with some definitions. Part
211, on the other hand, details the specific organization and personnel within a quality control
23

unit (§211.22 - 211.34), as well as the design, lighting, ventilation, plumbing, maintenance of,
and equipment type to be used in, quality control units (§211.42 - 211.72). The section also
details production and process control of pharmaceuticals, as well as packaging and labeling
control (§211.100 - 211.137). There are also regulations for laboratory controls, including
testing, samples, and animals within a lab (§211.160 - 211.176). The section concludes with
regulations regarding reporting, including equipment cleaning logs, batch production records,
and laboratory records (§211.180 - 211.198). GMPs, and regulations for GMPs, are important in
pharmaceutical drug manufacturing because consumers cannot easily detect an unsafe,
ineffective, or “bad” drug by looking at it, smelling it, touching it, or even ingesting it. GMP
testing is typically performed on small samples within a larger bath to ensure that the rest of the
batch is high quality and safe, effective, and “good” for human use.

Drugs; Official Names and Established Names
Part 299 describes the “official name” of a drug. This section is important to standardize
what people are calling drugs. While a lot of pharmaceutical drugs tend to have a generic name,
in addition to their official name, it would be confusing to have multiple different names for the
same drug.

Sections Excluded from State Analysis
Part 205 of the CFR is regulations for state licensing of wholesale prescription drug
distributions. The CFR states, “This part applies to any person, partnership, corporation, or
business firm in a state engaging in the wholesale distribution of human prescription drugs in
interstate commerce” (§205.1). Since each state has different policies on medical marijuana,
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there is no interstate distribution, therefore making it fair that this part of the CFR is exempt from
being analyzed.
Part 206 of the CFR is imprinting of solid oral dosage form drug products for human use.
While medical marijuana is allowed in pill form in many states, this FDA requirement is
specifically for pills that are going to be introduced into interstate commerce, stating that “no
drug product in solid oral dosage form may be introduced or delivered for introduction into
interstate commerce unless it is clearly marked or imprinted with a code imprint” (§206.10).
With that, and due to the lack of interstate commerce mentioned above, it is fair that this part of
the CFR is exempt from being analyzed.
Part 207 of the CFR outlines the requirements for foreign and domestic establishment
registration and listing for human drugs, including drugs that are regulated under a biologics
license application, and animal drugs, and the National Drug Code. The purpose of this part is to
register establishments that manufacture, repack, relabel, and salvage drugs. The FDA keeps
record of this, as well as drug listing information, allowing the FDA to have a current inventory
of drugs that are manufactured, repacked, relabeled, or salvaged for commercial distribution and
where. According to the FDA, “the information facilitates implementation and enforcement of
the Federal Food, Drug, and Cosmetic Act and is used for many important public health
purposes” (§207.5). States each have their own way of registering dispensaries, and
manufacturers or medical marijuana, since states have a variety of different agencies in charge of
their medical marijuana programs.
The following parts are not analyzed due to the lack of applicability to medical
marijuana: Part 212, regarding good manufacturing practice for positron emission tomography
drugs; Part 216, regarding human drug compounding; Part 225, regarding good manufacturing
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practice for medicated feeds; Part 226, regarding good manufacturing practice for type A
medicated articles; Part 250, regarding special requirements for specific human drugs; and Part
290, regarding controlled drugs.
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State Level Regulations of Medical Marijuana
Each state with medical marijuana policies creates their legislation and regulation in a
different way. Within the past 22 years, 32 states have legalized and regulated marijuana for
medical use. In terms of how that state legalized medical marijuana, 15 states legalized through a
Senate or House bill. Similar to the United States government, this means that the Senate or
House within the state’s legislature proposes the bill and both parties must agree on it. After that,
it can be signed by the governor to turn into law. Three states legalized medical marijuana
through an indirect initiated state statute, which is initiated by citizens through the collection of
signatures. After that, the state legislature can alter it, deny it, pass it, or draft a new copy and
post both on a ballot for voters to decide upon. Four states legalized medical marijuana through
an initiated state statute, which is similar to an indirect initiated state statute, except it goes
directly from the collection of signatures to the ballot for a vote. Three states have legalized
through an initiated constitutional amendment, which is similar to the state statute but it directly
amends that state’s constitution and the exact process varies by state. Some states have specified
the process of regulation in a separate document than that which legalized medical marijuana.
For example, Arizona legalized medical marijuana through an initiated state statute, but then had
a separate Senate Bill passed to discuss the regulation of medical marijuana (Americans, 2018).
Approximately half of the states that have legalized medical marijuana, however, also mentioned
the regulation process in the same document.
Within the regulation documents, each state specifies which department in each state will
be responsible for regulating medical marijuana. This varies dramatically by state. Some states
utilize the Department of Health, like Oregon and Hawaii. Other states create new offices and
departments that typically fall under the Department of Health. This includes Minnesota, which
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calls their new department the Office of Medical Cannabis. Other states, such as Michigan and
Connecticut, use the state’s current Department of Licensing & Regulatory Affairs. Some states
even use the Department of Agriculture, such as Illinois and California. Other states also use a
combination of multiple state departments involved in the regulation. While the regulation
specifically varies between each state, all states that have regulation do have some common
threads - including labelling, dispensaries, testing, and which medical conditions medical
marijuana applies to.
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Comparison
To some degree, many FDA regulations are reflected within the state regulations. Table 3
shows FDA regulations and states that have policies correspond to different areas of FDA
pharmaceutical regulation. The sections below will more specifically discuss which FDA
regulations overlap with state policies. Tables 4 through 9 are derived from Table 3, breaking
down each FDA policy into a more specific table.

Table 3: Areas of Coverage in State Regulations vs FDA Regulations
States

FDA
Policies

AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA

Labeling

x

x

x

x

Prescription
Drug Advertising

x

x

x

x

x

x

x

Prescription
Drug Marketing

x

x

x x x

x

x

Medication
Guides for
Prescription
Drug Products

x

x

Requirements for
Authorized
Dispensers and
Pharmacies to
Distribute a Side
Effects Statement

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x x

x

x

Current GMP in
Manufacturing,
Processing,
Packing or
Holding of
Drugs; General
Current GMP for
Finished
Pharmaceuticals
Drugs; Official
Names and
Established
Names

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x x x

x

x

x

x

x

x

Labeling
29

The labeling section of the CFR is broken into specific regulations that the FDA is
required to follow when regulating pharmaceutical drugs. There is some overlap when it comes
to states following these specific regulations in their regulation of medical marijuana. Table 4
shows the specified regulations and which are common, or uncommon, amongst states. All 23
states have regulations regarding the labeling of medical marijuana. 19 of 23 states also require
medical marijuana labels to have the name and location of the business manufacturer, packer, or
distributor. Additionally, 16 of 23 states have regulations regarding the clear statement of
ingredients on the label. Another common regulation is the significance of control numbers. 18
of 23 states require labels to have a control, lot, harvest, or batch number that can be easily
tracked back to the manufacturer, distributor, and facility. 13 of 23 states also have regulations
regarding the truth and accuracy of all statements on the label. Some less common regulations
include the label having adequate directions for use, which was implemented in 7 of 23 states; an
expiration date, which was implemented in 10 of 23 states and is optional in Washington state.
Specific formatting, which is referred to as “Prominence of required label statements” was
implemented in 3 of 23 states. Some aspects of FDA pharmaceutical regulations are not reflected
in state policies at all, including National Drug Code numbers and Spanish-language versions of
required statements. However, it is understandable that medical marijuana doesn’t not have
National Drug Code numbers because it is nationally labelled as a Schedule I drug.
In addition to states adopting some FDA regulations, some states have also implemented
supplemental regulations. Table 4 summarizes the labeling regulations for each state. Above the
colored line is policies found in the FDA standards, while below the colored line are additions
made by states not found in FDA standards. This includes regulations such as the printing of
patient name or registry identification number on the label, which was implemented in 10 of 23
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states; an allergen warning, which was implemented in 8 of 23 states; and the list of all nonorganic products used in the cultivation of medical marijuana, which was implemented in 4 of 23
states. 15 of 23 states have added a regulation of labeling the medical marijuana with the specific
strain or potency of the marijuana. 17 of the 23 states require the label to have the net weight or
quantity of marijuana in the package that is being labelled. Additionally, 13 of 23 states require
the label to be not attractive to children, and many states include the complete omission of any
pictures or infographics to appeal even less to children.
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Table 4: Labeling Regulations of States
States
AZ CA
Name & Place of
manufacturer, packer, or
x
distributor

x

CO

CT

x

x

DE

DC

HI

IL

ME

MD

MA

MI

MN

MT

x

x

x

x

x

x

x

x

x

NV

NH

NJ

NM

NY

x

x

x

x

OR

RI

VT

x

WA

x

National Drug Code
numbers
Adequate directions for
use

x

Misleading statements

x

x

Statement of ingredients

x

x

Prominence of label
statements

x
x

x

x

x

x

x

x

x
x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x
x

x

x

Spanish-language
Location of expiration
date
Significance of control
numbers

x
x

x

x

x

x
x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

optional

x

x

x

x

x

x

x

x

Additional Policies Added by States
Patient's Name or
Registry ID Number

x

x

Shall not be made
attractive to children

x

Allergen Warning

x

Net Weight

x

x

x

x

x

List of cultivation
nonorganic pesticides,
fungicides, & herbicides

x

Date of Dispensing

x

Strain / Potency

x

x

x

x

x

x

x
x
x

x
x

x

x
x

x

x

x

x

x

x
x

x

x

x

x

x
x
x

x

x
x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x
x

x

optional
x

x
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Prescription Drug Advertising and Prescription Drug Marketing
The CFR is broken into both an advertising section and a marketing section. 14 of the 23
states have regulations regarding marketing and advertising. However, seven of the states with
advertising and marketing regulations encompass marketing and advertising into one category, as
opposed to separating them. Another six of the states only have advertising requirements, and do
not mention marketing at all. Oregon is the only state with both advertising and marketing
requirements. Montana is the only state with only one advertising regulation, which is that
advertising is prohibited. No states have regulations regarding the use of the drug’s official name
on the advertisement or regulations regarding the ingredients of the drug on the advertisement
having to match that on the label. 10 of the 23 states have regulations regarding the truth and
accuracy of statements on advertisements, and 5 of the 23 states have regulations outlining
different types of advertisements. Only four states have regulations regarding samples of medical
marijuana being used for marketing. Of those four, three states have only one regulation: samples
for marketing purposes are prohibited. 9 of 23 states do have some type of regulation regarding
the maintenance, security, or content of records and receipts, similarly to FDA regulations. No
states, however, have any marketing regulations regarding re-importation or sales restrictions.
In addition to states adopting some FDA regulations, some states have also implemented
supplemental regulations. In Table 5, all regulations below the colored line are additions made
by states. Six states implemented a policy that prohibits advertisements and marketing to be
toward minors. Three states do not allow advertisements to encourage the use of medical
marijuana for anything other than that states’ approved list of debilitating medical conditions.
DC has a marketing policy that indicates that dispensaries must have a plan for marketing prior
to becoming an approved dispensary.
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Table 5: Marketing and Advertising Regulations of States
States
AZ CA CO CT DE DC HI IL ME MD MA MI MN

MT

NV NH NJ NM NY OR RI VT WA

Advertising Guidelines
No "unofficial" names
Ingredients must match label
Types of Advertisements

x

Misleading Statements

x

x
x

x

x

x

x

x

Advertising is
prohibited

x

x

x
x

x

x

Marketing Guidelines
Reimportation
Sales Restrictions
Samples

x*

x*

x*

Wholesale Distribution

x

Request & Receipt Forms, Reports and
Records

x

Additional Policies Added by States
Ads cannot encourage use of marijuana for
anything other than debilitating medical
conditions

x

Dispensary application must offer a
marketing plan
No advertising or marketing to minors

x

x

x

x

x

x

x

x

x

x
x

x

x
x

x

x

x

x

x

x* = while there is a regulation in place, the regulation prohibits samples
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Medication Guides for Prescription Drug Products
Of the 23 states being analyzed, only five states have policies regarding medication
guides for medical marijuana, which can be seen in Table 6. These states typically refer to them
as patient education, or patient information. The FDA only breaks their regulation into two parts:
content and format. Their content is quite extensive and while four states have regulations
regarding what specifically needs to be in their patient educational materials, the regulations are
nowhere near as extensive as the FDA. Only one state requires a specific format, mostly
specifying font size and type, and not specifying headings or organization - like the FDA
regulations do. Vermont is the only state that has no content or format regulations, but does
specifically state that dispensaries are required to provide patient educational materials. Maine
and Massachusetts also require the distribution of patient educational materials, while New
Hampshire and New Jersey just require the materials to be available for qualifying patients and
caregivers.

Table 6: Medication Guide Regulations for States
States
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA
Content

x

x

Format
Distributing /
Dispensing

x

x

x
x

x

x

Requirements for Authorized Dispensers and Pharmacies to Distribute a Side Effects Statement
There are nine states that have regulations regarding the distribution of a side effects
statement. Similar to the FDA regulations for medication guides, the FDA only breaks their
regulations into two parts for side effects statements: content and format. 7 of the 23 states have
content regulations, but four of those states only have the content of their side effects section
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requiring a statement regarding the limited information available on the side effects of medical
marijuana. No states have formatting regulations, while 4 of the 23 states have regulations about
how to distribute or dispense the side effects statement.
In addition to states adopting some FDA regulations, some states have also implemented
supplemental regulations. In Table 7, the regulation below the colored line is an addition made
by states. 2 of the 23 states require any side effects statement to be true, accurate, and not
misleading.

Table 7: Side Effects Regulations for States
States
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA
Content

x

x-

x-

x-

x

x

x

x

x-

Format
Distributing
/ Dispensing

x

Additional Policies Added by States
True / Not
Misleading
x

x

x

x- = while there is a regulation in place, the content states: “There is limited information
available on the side effects of medical marijuana”

Current GMP in Manufacturing, Processing, Packing of Holding of Drugs; General and Current
GMP for Finished Pharmaceuticals
The GMPs sections of the CFR is broken into specific regulations that the FDA is
required to follow when regulating pharmaceutical drugs. There is some overlap when it comes
to states following these specific regulations in their regulation of medical marijuana. 18 of the
23 states have regulations regarding GMPs. Table 8 shows the specified regulations and which
regulations are common, or uncommon, amongst states. 8 of the 23 states have a general
regulation as to how the quality control unit must be organized and 12 of the 23 states have
regulations regarding personnel. These regulations vary, as some states have outlined very
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specific training, specific onboarding processes, and others have extensive background checks
and files on all personnel. The FDA also specifies building or facilities design and maintenance,
and 13 of the 23 states have regulations regarding their facilities. However, these regulations are
not specific, since some states only specify the sanitation of the building, or describe that the
building must be deemed safe by fire and town officials, or be suitable for the manufacturing,
packaging, or dispensing of medical marijuana. Similarly, 14 of the 23 states have regulations
regarding the equipment used in the facility - however, they are also vague, and most only
specify that the equipment should be sanitary. Laboratory controls and record keeping are both
common regulations, as 18 of 23 states have regulations regarding them. Since only four of 23
states have a regulation regarding holding/distribution and only 3 of 23 states have a regulation
regarding production & process controls, these are much less common amongst states.
Some states have also implemented regulations that go beyond FDA standards. In Table
8, all regulations below the colored line are additions made by states. This includes regulations
such as security equipment being on the premises, which has been implemented in 18 of 23
states; specific waste disposal regulations, which has been implemented in 13 of 23 states; and
location of dispensaries or other facilities in relation to schools, churches/other places of
worship, or pre-designated drug-free zone, which has been implemented in 14 of 23 states.
Distance between the medical marijuana facility and off-limits location varies, from a 50-foot
radius, to 300 feet away, to 1000 feet away. Some states even include public swimming pools,
playgrounds, and day-care facilities in their regulations (NV).
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Table 8: Good Manufacturing Practices Regulations of States
States
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA
QC Organization

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

QC Personnel

x

Buildings/Facilities Design and Maintenance

x

Equipment Requirements

x

x

x

Drug Storage (Containers and Closures)

x

x

x

x

Production & Process Controls
Packaging and Labeling Control

x
x

x

Holding/Distribution

x

x

x

x
x

x

x

x

x

x

x

x

x

x

x

x

x
x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x
x

x

x

x

x

x

x

x

x

x

x

Laboratory Controls

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

Records and Reporting

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

Additional Policies Added by States
Security
Waste Disposal
Distance from School

x

x

x

x
x

x

x

x

38

Official and Established Drug Names
The FDA section regarding established names of drugs specifies that pharmaceutical
drugs should use their official name and avoid the use of “other names.” 21 of the 23 states being
analyzed have regulations regarding the definition of medical marijuana and regulations to avoid
the use of street names, and use only the defined definition of medical marijuana in that specific
state, which can be seen in Table 9. Nevada and Montana are the only states that do not specify
the definition of their medical marijuana.

Table 9: Drug Name Regulations of States
States
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA
Official
Name

x

x

x

x

x

x

x

x x

x

x

x

x

x

x

x

x

x

x x

x

Avoid Use
of "Other
Names"
x

x

x

x

x

x

x

x x

x

x

x

x

x

x

x

x

x

x x

x

Other Regulations Added by States
In addition to states adopting policies that compare to FDA regulations, states have
implemented additional policies related to medical marijuana that focus less on safety and more
on the social aspects of medical marijuana. Table 10 shows these additional regulations and
which states have implemented a policy for each regulation. 10 of 23 states have implemented a
policy regarding the anti-discrimination of employees. This means that states are not allowed to
deny employees because of their status as a medical marijuana patient. 11 of 23 states have
implemented policies regarding employee drug tests. 5 of 23 states have a policy that they cannot
deny or fire employees based on a marijuana-positive drug test, if they are medical marijuana
patients. 6 of 23 states have a policy that they can deny or fire employees for a marijuanapositive drug tests, regardless of their status as a medical marijuana patient. 9 of 23 states have a
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policy that prohibits the smoking or vaping of medical marijuana in various public places. 9 of
23 states have a policy regarding impaired driving. For five of those states, the policy is zero
tolerance – meaning driving under the influence of marijuana, even if one is a medical marijuana
patient, is illegal. However, the other four states have a policy that allows medical marijuana
patients to have a minimal amount of marijuana in their system while driving.

Table 10: Additional Regulations Added by States
States
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA
AntiDiscrimination
Regarding
Employees

x

AntiDiscrimination
Regarding
Employee Drug
Tests
x
Positive Drug
Test
(Employers)
Prohibits
Smoking/Vaping
in one or more
of the following
venues: nonhospitality
workplaces,
restaurants, bars
and/or gambling
facilities
Impaired
Driving (Zero
Tolerance
policy)
x
Impaired
Driving
(minimal
amount allowed)

x

x

x x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x x

x

x

x

x

x
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Chapter VI. Analysis
State regulations regarding medical marijuana have some variation, particularly when
compared to specific sections of the FDA’s CFR for pharmaceutical drugs. However, states are
implementing additional policies that go beyond the FDA regulations, allowing for the
mitigation of additional risks associated with medical marijuana legalization. As seen in the
literature review, studies found that safety and efficacy, increased use, youth use, public health
effects, traffic incidents, crime rates, and suicide rates were common concerns associated with
the legalization of medical marijuana. Many, although not all, of these concerns are addressed in
state legislation. This can be seen, for example, with the additional policies added by states
revolving around children, such as the distance of facilities from a school and not advertising to
minors. These policies are geared specifically toward decreasing increased youth use.

Labeling
Within the labeling section, states have adopted a majority of the regulations already set
out by the FDA for pharmaceuticals. The few regulations that are not being adopted include the
use of National Drug Code numbers and a Spanish-language version of certain required
statements. Since medical marijuana is still illegal on a federal level, it is impossible for states to
use National Drug Code numbers. Many FDA regulations regarding labeling are reflected in
state regulations. Labeling requirements are important to ensure the product is safe and patients,
caregivers, physicians, manufacturers, and dispensaries are getting accurate information about
the products. Some states have implemented additional policies including adding the patient’s
name or registry ID number to the label, as well as an allergen warning, the net weight or
quantity, date of dispensing, strain/potency, and list of all non-organic pesticides, fungicides, and
herbicides used during cultivation - as seen in Figure 3. The implementation of these policies
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adds an additional level of safety to medical marijuana. Considering the reason that the FDA has
policies on labeling is to ensure product safety, the states are adding policies to their legislation
that is applicable to medical marijuana and continues to ensure the safety of the product. An
important added regulation in 13 of the 23 states is that labels cannot be made attractive to
children, including the complete elimination of color or cartoons. This helps mitigate the
commonly seen risk of increased youth use. More states should adopt a policy regarding the
labels being unappealing to children, and the FDA could also learn from this. According to the
National Survey on Drug Use and Health from 2014, nearly 6,000 youth reported using
prescription pain relievers without a doctor’s guidance for the first time (Volk, 2014).
Additionally, in 2017, there were 1,031 reported prescription drug overdoses in teens (age 1524), while there were no reports of teens or young adults dying from a marijuana overdose (The
National Institute, 2017). Since it is reported that marijuana overdoses are uncommon, but
prescription drug overdoses are common, the FDA could think about implementing policies
regarding distance of facilities, pharmacies, etc. from schools and other places that children,
teens, and young adults frequent.

Marketing & Advertising
While the FDA separates marketing and advertising regulations into separate sections,
states consider them to be the same. With that, the states that have marketing and/or advertising
regulations tend to focus more on advertising instead of marketing. Even then, the states focus on
the advertisements being true, accurate and not misleading, as well as keeping records of sales
and being able to report to the local government if requested. This is important, considering the
regulations regarding advertising also revolve around product safety and ensuring that patients,
caregivers, physicians, manufacturers, and dispensaries are getting accurate information about
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the products. Having true, accurate, and not misleading advertisements is key when it comes to
getting accurate information. Routine reporting also plays a key role in product safety, so the fact
that states keep records is also important. States also implemented additional marketing or
advertising regulations, such as prohibiting advertisements from encouraging use for anything
other than that states list of medical conditions and prohibiting advertising and marketing to
minors. These regulations mitigate risks that the FDA doesn’t focus on, such as increased use
and youth use, respectively. As with the labeling requirements, the FDA could adopt similar
policies for prescription drugs.

Medication Guides
Medication guides are required by the FDA for every prescription drug. The FDA also
outlines how and when the medication guides are to be distributed to patients. However, only
five states have a policy regarding medication guides, which they often refer to as patient
education materials or patient informational guides. The FDA has very specific content and
format for medication guides, giving exact headlines that need to be in the guide and font size.
The states have more vague regulations, often neglecting format entirely and having a basic
content outline. Medication guides are important to give patients, caregivers, and physicians
accurate information about the drug. Since there are differences in strain and potency of medical
marijuana, medication guides should be even more necessary and states are highly lacking in this
respect.

Side Effects Warning
The data shows that states are lax on requiring a side effects warning, which are required
for all drugs by the FDA; only 9 states have adopted a similar policy for medical marijuana. 4 of
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the 23 states only have a regulation stating that the side effects warning must read “There is
limited information available on the side effects of medical marijuana.” Issuing a side effects
warning is important so that patients know what could potentially happen while taking the drug.
However, the majority of known side effects come about through clinical trials. Since clinical
trial data is required for all prescription drugs to be approved by the FDA, it is an important step
that states are missing during their legalization of medical marijuana. However, states are not
legalizing medical marijuana the same way the FDA legalizes prescription drugs. Instead, states
legalize medical marijuana through Senate bills, constitutional amendments, etc., meaning states
are less aware of potential side effects.

Good Manufacturing Practices
In terms of good manufacturing practices (GMPs), states have adopted many policies
similar to the FDA. GMPs are important to ensure the safety of the product, so it is important
that states are following these procedures. There are a few states (Arizona, Vermont) that
actually don’t have any GMP regulations addressed and these states should absolutely add some,
since GMPs are important in product safety. States have also implemented security measures at
their manufacturing and/or dispensing facilities, which is important since marijuana is still a
Schedule I drug according to the federal government. The security measures ensure that only
authorized personnel are entering the facility, adding an extra safety measure to the
manufacturing and dispensing of medical marijuana. Additionally, many states added policies
regarding waste disposal. Similar to the security measures, disposing of marijuana must be
addressed since it is federally illegal. Lastly, another commonly added policy is in regards to
facilities’ distances from a school, church, place of worship, playground, daycare center, or
another already identified drug-free zone. This addresses a concern specific to legalizing medical
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marijuana, which is increased youth use of marijuana. Requiring facilities to be distanced from
places that are frequently occupied by children could help to mitigate this risk. For the most part,
however, states have adopted many aspects of the FDA regulations regarding good
manufacturing practices.

Official Drug Names
The FDA regulates the use of official drug names and not using any other names that are
not considered “established” for that drug. This is important since it would be confusing to have
many different names for the same drug. However, there is no official definition or name for
medical marijuana, since there is a slight variation between states. With that, there is no
standardization for what is considered to be medical marijuana and what is not. Regulating at the
federal level could definitely help in this respect, since the FDA would be able to standardize this
definition, allowing for less variation. Along similar lines, there is no consensus between states
regarding which medical conditions can be treated using medical marijuana. For example, while
most states have a list with similar conditions on them, Maine has no list of approved conditions
and physicians are allowed to recommend medical marijuana for any condition they wish
(ProCon.org, 2019).
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Chapter VII. Discussion and Conclusion
Through this research, it is evident that the FDA outlines important regulations to
regulate prescription drugs and that each regulation is in place for a reason, mitigating risks
regarding the safety of patients and product quality. States have adopted some regulations in line
with FDA regulations, but states have also introduced many additional areas of policy. These
new policies mitigate additional risks, particularly in areas that are of high social concern such as
increased drug use and youth use. For example, states with additional laws limiting advertising to
minors and distancing medical marijuana facilities or dispensaries from schools are taking action
to reduce the issue of increased youth use. Medical marijuana is a complex social issue. States
can integrate potential solutions to social issues into medical marijuana policies. While states are
creating policies for safety reasons and to maintain product quality, they have the opportunity to
also integrate policies that address the broader social context, which is something the FDA
currently does not do. It is in this respect that policy innovation can really happen at the state
level.
Since there is no level of federal standardization considering the illegality of marijuana,
states are also creating policies that are vastly different from other states. While some of these
discrepancies could be seen as positive policy disagreements, since states are just disagreeing
over the scope to which medical marijuana should be regulated (Robert, 2011), the discrepancies
should still be remedied since medical marijuana is being utilized as a medication. A remedy to
this issue is to reschedule marijuana in a lower drug classification (Schedule II or lower). If that
were to happen, the FDA could become involved in regulating marijuana, since it would be
allowed for medical use. This would allow for approval of medical marijuana based on scientific
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evidence of the benefits or negative effects, from extensive clinical trials that would be required
by the FDA for drug approval, as opposed to political considerations.
A commonly suggested idea to mitigate risks like increased marijuana use is to mandate
that physicians tell their patients all of the risks of the medical marijuana they are
recommending. Several studies (Davis, 2016; Hill, 2015; Grant, 2012) identify that the
implementation of medical marijuana laws should come with public education of overdose
statistics and other important information, as well as benefits/risks regarding the use of medical
marijuana. Additionally, physicians should begin looking deeply into their patients’ history
before recommending medical marijuana as a treatment, looking particularly at the potential for
misuse, abuse, and addiction.
Regarding the future involvement of the FDA in the regulation of medical marijuana, one
idea would be for the federal government to reschedule marijuana as a Schedule II, or lower,
drug. After that, marijuana would be eligible for use as a medical drug and the FDA would be
involved in the regulation of the drug. The FDA requires numerous tests and trials to be
conducted in order to determine if a drug is safe and efficacious. The FDA’s regulations would
create much stricter rules for obtaining, taking, and prescribing medical marijuana. The
standardized approach of the FDA could drastically decrease all of the risks felt by the states that
have legalized medical marijuana on their own terms and increase the safety of medical
marijuana that states are lacking. However, with marijuana’s current status, it can be seen that
policy innovation is occurring as states build their own policies regarding marijuana for medical
use and are allowed to look at drug safety in a broader context. However, without the
standardization from the FDA, states are lacking in their general safety policies and potentially
risking the safety of their medical marijuana patients.
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Limitations
There are some limitations to this research. First and foremost, marijuana is illegal at the
federal level. This means that information is fairly limited in general. It also means that states
cannot conduct as much research on marijuana. While states can still conduct FDA-approved
clinical trials on medical marijuana, the samples must be supplied by the federal government. IN
fact, many clinicians have complained that the federally supplied marijuana is of inferior quality,
limiting the quality of these studies (Armentano, 2019). Additionally, the topic of medical
marijuana is fairly new, so there is – in general – not a lot of extensive research conducted in the
area. My research also did not analyze the quality of the regulations been compared to the FDA.
While there was overlap between states’ regulations and FDA regulations, there was little to no
analysis of the quality of the regulations. While I compared which states had which aspects of
FDA regulations, there was no analysis into how the state regulations compared to the
regulations of the FDA. Therefore, additional analysis could be conducted to determine if the
state regulations are on the same level as the FDA or not.
Another limitation while conducting research was the lack of analysis of enforcement of
medical marijuana laws. While all states have specific organizations that regulate and enforce
medical marijuana, there was no analysis of how this occurs. Many states have multiple
departments, or a new branch of a department, serving as the regulator and enforcer of medical
marijuana laws. Not studying this could limit research because, while states have these policies
in place, it is not specified how states go about ensuring the policies are enacted and done so
properly, and up to the standards of the state.
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Implications for Future Research
It is clear that additional research should be conducted regarding the implications of state
level medical marijuana laws; much of the current research is limited and inconclusive. One
noticed absence in existing research was a focus on potency and efficacy. This suggests that
more research should be conducted in the realm of clinical trials. States conducting clinical trials
on their own terms could allow policymakers to make more informed decisions on medical
marijuana policies by using scientific evidence to back up their claims. However, because of the
dual legality of marijuana in the United States, this will likely continue to prove to be difficult.
Future research, on the other hand, could utilize information from other countries to make
decisions. So far, 21 countries or territories have legalized cannabis fully or partially, for medical
or recreational use (MacIver, 2017). Incorporating more countries in a future study could provide
insight into the legalization of medical marijuana, as well as potential side effects or analysis of
clinical trial studies. Many countries do not have a national agency to regulate clinical trials like
the United States, so looking at data from additional countries that have more freedom with
clinical trials could provide much more insight and more information than what is known in just
the United States.
Further research could be conducted in the realm of what the federal government can and
cannot do to states with medical marijuana policies. While patients were given some leeway
under the Obama administration, dispensaries are facing penalization by the federal government.
For example, the Internal Revenue Service (IRS) has audited multiple dispensaries, referencing
on a section of the federal tax code that prohibits companies from deducting expenses related to
drug trafficking – alleging that dispensaries owe millions in back taxes. Steve DeAngelo, owner
of a dispensary in California that serves more than 100,000 customers and from whom the
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federal government says owes $2.4 million, says “No business in America could survive if all of
its expense deductions were disallowed. This is not an attempt to tax us. It’s an attempt to tax us
out of existence” (Scott, 2012). While states are technically allowed to make their own policies
regarding medical marijuana, the federal government may still be making efforts to interfere.
Additional research could be conducted to see what impact this has on states’ medical marijuana
programs.
Additional research could be conducted regarding the enforcement of medical marijuana
laws within each state. Looking at whether, or not, states are abiding by the policies and doing so
in a manner that is up to par with the states’ requirements could shed light on the actual impacts
of the policies. Analyzing the enforcement process could determine if states are ensuring that
policies are where they need to be and can ensure the safety of patients and product. For
example, the Colorado Department of Agriculture takes random samples of marijuana, as it does
for all crops. By doing so, it discovered 22 cases of pesticide misuse in 2018 (Hoing, 2019).
While the process likely varies from state to state, studying how the enforcement occurs could
help protect patient safety, ensure product quality, and even keep cultivation facilities and
dispensaries sanitary.
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Implications for Policy
Recommendation: The federal government should reschedule marijuana as a Schedule II
or III drug, so that it can be used for medical purposes.
While marijuana remains a Schedule I drug according to the federal government, states
around the United States are deciding to legalize marijuana for medical—and in some cases,
recreational—use. This is an intriguing situation, since allowing a substance to be a medicine but
also utilized for recreational purposes really complicates the perception of the substance. One
article (Clark, 2011) discusses the ethical, legal and medical perspectives in regards to the
legalization of medical marijuana. Clark believes that not legalizing medical marijuana denies
patients the right to potentially beneficial treatments and to deny them this is a violation of their
basic human rights. Additionally, the author looks at the legal perspective – describing how,
since marijuana is still classified as a Schedule I drug federally, it becomes difficult to formulate
laws at a state level that do not break federal law. This gives perspective into how new policies
should be created regarding medical marijuana. Since it is being used as a medical drug, it would
make sense for the FDA to begin regulating medical marijuana. This would mean a rescheduling
of marijuana as either a Schedule II or Schedule III drug. Changing the status of marijuana
would allow physicians to prescribe medical marijuana and mean that the FDA would be
responsible for all regulations. Additionally, advocates of rescheduling marijuana look at the
economic impact it would have. Legalizing the use of marijuana in the United States would save
an estimated $8.7 billion, by reducing government spending for drug enforcement in the criminal
justice system (Miron, 2010). Legalizing drugs and taxing them in a way that is comparable to
alcohol and tobacco would create additional revenue. Rescheduling marijuana could be a step in
the right direction of adopting a better regulatory framework.
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Recommendations if the federal government does not reschedule marijuana and states are
left to continue making their own policies on medical marijuana: states need to increase the
stringency of their regulations to ensure that safety is a higher priority.
There have already been multiple petitions in history to reschedule marijuana. However,
the federal government has denied every one of them. The rescheduling process is a long and
complicated one. Some complication comes from the idea that rescheduling requires a lot of
input from many administrative bodies, such as the President, the Attorney General, the Drug
Enforcement Administration, and the Department of Health and Human Services (Rough, 2017).
If the federal government continues to deny petitions for rescheduling, the states would remain
responsible for the regulation of medical marijuana. On one hand, this could allow states to
innovate the way they regulate medical marijuana, allowing them to integrate new policies that
could mitigate additional risks that the FDA doesn’t currently consider for pharmaceutical drugs.
However, it could also mean that states continue on their current path of focusing less on safety.
It can be seen that many states do not adopt policies along the same lines as the FDA and, while
some do, they are not as detailed or extensive as the FDA. This could mean the addition of health
and safety risks, since the standardization is low or non-existent. Not rescheduling marijuana
would mean that states need to increase the rigidity of their regulations, in an effort to make sure
that safety is a higher priority.
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Conclusion
Medical marijuana is a controversial issue. The duality of legislation places marijuana on
the federal government’s list of Schedule I drugs, while states are legalizing it on a local level.
Previously conducted research focused on the risks that occurred after the implementation of
medical marijuana laws. My research focused on FDA regulations for pharmaceutical drugs and
whether, or not, states have implemented similar regulations in order to ensure the safety of
patients and products. The FDA’s overarching mission is public health and safety, so FDA
regulations are crucial in ensuring those goals are met. While my research found some overlap
between state regulations and FDA regulations, it was found that states’ regulations are not
enough to ensure the safety of medical marijuana products and patients. States are, however,
implementing additional policies to mitigate some risks that were found to have occurred after
the implementation of medical marijuana laws, including increased youth use and public health
effects.
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Appendix
Appendix 1: Table Obtained from National Conference of State Legislators and Documentation & Departments Involved in Medical
Marijuana Legalization and Regulation
Obtained from National Conference of State Legislators

Documents and Departments Responsible for Medical
Marijuana Legalization & Regulation

http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx

State

AZ

CA

CO

CT

DE

Statutory
Language
(Year)

Patient
Registry or ID
cards

Proposition 203
(2010)
Yes

Proposition 215
(1996) SB 420
(2003)
Yes

Amendment 20
(2000)

Yes

HB 5389 (2012) Yes

SB 17 (2011)

Yes

Allows
Dispensaries

Yes

Specifies
Conditions

Yes

Yes
(cooperatives
and collectives) No

Yes

Yes

Yes

Yes

Recognizes
Patients from
other states
Yes, for AZapproved
conditions, but not
for dispensary
purchases.

No

No

Yes

Yes

State Allows
for Retail Sale
/ Adult Use

Yes, for DEapproved
conditions.

Regulated and
Enforced by:

Dept of Health
Services

Legalization
Document

Regulation
Document

Yr

initiated state
statute

Senate Bill

2010

initiated state
statute

Medicinal &
Adult-Use
Cannabis
Regulation and
Safety Act

1996

Yes

over a dozen
organizations

Yes

Dept of Revenue,
Marijuana
initiated
Enforcement
constitutional
Division
amendment

Colorado
General
Assembly

2000

Dept of Consumer
Protection,
Medical
Marijuana
Program
House Bill

Same House Bill
that legalized

2012

Delaware Health
and Social
Services, Division Senate Bill

Same Senate Bill
that legalized

2011
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of Public Health,
Office of
Medicinal
Marijuana

DC

HI

Initiative 59
(1998) L18-0210
(2010)
Yes

SB 862 (2000)

Yes

IL

HB 1 (2013) Eff.
1/1/2014
Rules
Yes

ME

Question 2
(1999) LD 611
(2002)
Question
5(2009) LD
1811(2010)
LD 1296 (2011) Yes

MD

HB 702 (2003)
SB 308 (2011)
HB 180/SB 580
(2013) HB
1101-Chapter
403 (2013)
SB 923 (signed
4/14/14)
HB 881- similar
to SB 923
Yes

MA

Question 3
(2012)
Regulations

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

DC Council

DC Council

1998

Senate Bill

HB/SB multiple
amendments

2000

No

Dept of Health,
Medical
Marijuana
Dispensary
Program

No

Dept of Financial
and Professional
Regulation, Dept
of Health, Dept of
Agriculture
House Bill

Same House Bill
that legalized

2013

Yes, but not for
dispensary
purchases.

Dept of Health
and Human
Services, Division
of Public Health
Services, Medical
Use of Marijuana indirect initiated
Program
state statute

SB / HB / LD

1999

No

Maryland Medical
Cannabis
Commission
Senate Bill

HB

2003

No

Dept of Public
Health

Same indirect
initiated state
statute that

2012

Yes

Yes

indirect initiated
state statute

55

(2013)

MI

Proposal 1
(2008)

MN

SF 2471,
Chapter 311
(2014)

MT

Initiative 148
(2004) SB 423
(2011)
Initiative 182
(2016)

NV

Question
9(2000) NRS
453A NAC
453A

legalized

Yes

Not in state
law, but
localities may
create
regulations

Yes

Yes, limited,
liquid extract
products only

Yes

Yes

No**

Yes

Yes

Yes, for legal
protection of
possession, but
not for dispensary
purchases
Yes

Bureau of
Medical
Marijuana
Regulation, Dept
of Licensing and
Regulatory
Affairs

indirect initiated
state statute

House Bill

2008

No

Dept of Health,
Division of Health
Policy, Office of
Medical Cannabis Senate Bill

Same Senate Bill
that legalized

2014

Yes

No

Dept of Health & initiated state
Human Services statute

Same initiated
state statute that
legalized

2004

Yes

Yes, if the other
state's program is
"substantially
similar." Patients
must fill out
Nevada
paperwork. Adults
over 21 may also
purchase at adult
retail dispensaries. Yes

Senate Bill

2000

Yes

Dept of Taxation

initiated
constitutional
amendment
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Yes

Same House Bill
that legalized

2013

Same Senate Bill
that legalized

2009

Senate Bill

Same Senate Bill
that legalized

2007

NY Assembly

Same NY
Assembly that
legalized

2014

House Bills,
Senate Bills

1998

HB 573 (2013)

NJ

SB 119 (2009)
Program
information

Yes

Yes

Yes

No

Dept of Health &
Senior Services,
Dept of
Agriculture
Senate Bill

NM

SB 523 (2007)
Medical
Cannabis
Program

Yes

Yes

Yes

No

Dept of Health

A6357 (2014)
Signed by
governor 7/5/14 Yes

OR

Oregon Medical
Marijuana
Act(1998)
Yes

Yes

Dept of Health &
Human Services,
Office of
Operations
Support,
Therapeutic
Cannabis Program House Bill

NH

NY

Yes

Yes, with a note
from their home
state, but they
cannot purchase
through
dispensaries.

Ingested doses
may not
contain more
than 10 mg of
THC, product
may not be
combusted
(smoked).
Yes

No

Dept of Health

Yes

No, but adults
over 21 may
purchase at adult

Oregon Health
Authority, Oregon House Bills,
Medical
Senate Bills

Yes

Yes
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SB 161 (2007)

retail dispensaries.

Marijuana
Program
Dept of Health

RI

SB 791 (2007)
SB 185 (2009)

Yes

Yes

Yes

Yes

VT

SB 76 (2004) SB
7(2007) SB
17(2011)
H.511 (2018)
Yes

Yes

Yes

No

WA

Initiative 692
(1998) SB 5798
(2010)
SB 5073 (2011) No

Yes, approved
as of Nov.
2012, stores
opened in July,
2014.
Yes

No, but adults
over 21 may
purchase at an
adult retail
dispensary.

Senate Bill

Same Senate Bill
that legalized

2007

Yes

Dept of Public
Safety

2004

Yes

Dept of Health &
Liquor and
Cannabis Board
Initiated statute

1998
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Appendix 2: FDA Sections and States that Adopted Similar Policies

States
FDA Policies

AZ CA

CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA

Labeling

x

x

x

x

Prescription Drug Advertising

x

x

x

x

x

x

x

Prescription Drug Marketing

x

x

x

x

x

x x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x x

x

x

x

x

x

x

x

x

x

Guidelines for State Licensing of Wholesale
Prescription Drug Distributions
Imprinting of Solid Oral Dosage Form Drug Products
for Human Use
Requirements for Foreign and Domestic Establishment
Registration & Listing for Human Drugs
Medication Guides for Prescription Drug Products

x

Requirements for Authorized Dispensers and
Pharmacies to Distribute a Side Effects Statement

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x x

x

x

Current GMP in Manufacturing, Processing, Packing
or Holding of Drugs; General
Current GMP for Finished Pharmaceuticals

x

x

x

x

x

x

x

x

x

x

x

x

x x

x

x

x

x

x

x

Current GMP for Positron Emission Tomography
Drugs
Human Drug Compounding
Current GMP for Medicated Feeds
Current GMP for Type A Medicated Articles
Special Requirements for Specific Human Drugs
Controlled Drugs
Drugs; Official Names and Established Names

x

x

x

x
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